Peramivir: Another tool for influenza treatment?

Clinical Infectious Diseases

Volumn 52, Issue 6, 2011, Pages 707-709

  Jain, Seema ^a   Fry, Alicia M ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE DERIVATIVE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL THERAPY; COMORBIDITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MARKETING; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IC 50; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NOTE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RISK REDUCTION; SEASONAL INFLUENZA; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYCLOPENTANES; DRUGS, INVESTIGATIONAL; FEMALE; GUANIDINES; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PREGNANCY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 79953756895     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir010     Document Type: Note

References (21)

1. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 in- fluenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44.
2. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302:1896-902.
3. World Health Organization. Pandemic (H1N1) 2009 vaccine deployment update-27 September 2010. Available at: http://www.who.int/csr/disease/swineflu/ h1n1-vaccine-deployment-update20100927.pdf. Accessed 2 December 2010.
4. Centers for Disease Control and Prevention. Interim guidance on the use of influenza antiviral agents during the 2010-2011 season. Available at: http://www.cdc.gov/flu/professionals/antivirals/guidance/. Accessed 24 November 2010.
5. World Health Organization. WHO guidelines for pharmacologic management of pandemic influenza A (H1N1) 2009 and other influenza viruses. Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1-guideli nes-pharmaceutical-mngt.pdf. Accessed 9 November 2010.
6. Gubareva LV, Trujillo A, Okomo-Adhiambo M, et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther 2010; 15:1151-9.
7. Centers for Disease Control and Prevention. Flu activity and surveillance. Available at: http://www.cdc.gov/flu/weekly/fluactivitysurv. htm. Accessed 20 December 2010.
8. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361:2204-7.
9. Hernandez JE, Adiga R, Armstrong R, et al. The clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United States. Clin Infect Dis 2011; 52:695-706.
10. Sorbello AF, Jones SC, Carter W, Struble K. Safety of peramivir accessed under the FDA emergency use authorization (EUA) to treat hospitalized patients infected with 2009 H1N1 influenza virus[abstract V-648]. Program and Abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (Boston). Washington, DC: American Society for Microbiology, 2010.
11. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-75. (Pubitemid 351411840)
12. Lee N, Cockram CS, Chan PK, et al. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin Infect Dis 2008; 46:1323-4. (Pubitemid 351589924)
13. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al. Severe Human in- fluenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One 2009; 4:e6051.
14. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 Influenza A (H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:1517-25.
15. Louie JK, Acosta M, Jamieson DJ, Honein MA. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010; 362:27-35.
16. Zarychanski R, Stuart TL, Kumar A, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010; 182:257-64.
17. Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 2010; 341:c4779.
18. Farias JA, Fernandez A, Monteverde E, et al. Critically ill infants and children with in- fluenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med 2010; 36:1015-22.
19. Yang P, Deng Y, Pang Z, et al. Severe, critical and fatal cases of 2009 H1N1 influenza in China. J Infect 2010; 61:277-83.
20. Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10:521-6.
21. World Health Organization. Influenza (seasonal)-fact sheet No. 211. April 2009. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/index. html. Accessed 20 December 2010.